InvestSMART

Immuron Limited (ASX: IMC) - Announcements

- Current share price for IMC : $0.046

ASX company news and announcements for Immuron Limited (IMC) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Immuron Limited (IMC) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Immuron Limited (IMC), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Immuron Limited (IMC)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$15 Immuron Rights Issue Offer Booklet (May 2016) 31 May 2016 10:11AM $0.330 $0.046 fallen by 86.06%
$15 Letter to Ineligible Shareholders Regarding Rights Issue 31 May 2016 10:04AM $0.330 $0.046 fallen by 86.06%
$15 Letter to Eligible Shareholders Regarding Rights Issue 31 May 2016 10:03AM $0.330 $0.046 fallen by 86.06%
$15 Letter to Optionholders Regarding Rights Issue (May 2016) 31 May 2016 10:02AM $0.330 $0.046 fallen by 86.06%
$15 Section 708AA Notice (Rights Issue) 31 May 2016 10:00AM $0.330 $0.046 fallen by 86.06%
$15 Appendix 3B & 708A Notice 31 May 2016 9:58AM $0.330 $0.046 fallen by 86.06%
$15 Immuron Announces $6M Rights Issue Offer 31 May 2016 9:58AM $0.330 $0.046 fallen by 86.06%
$15 Trading halt 27 May 2016 9:08AM $0.330 $0.046 fallen by 86.06%
$15 NASH Phase II Trial Reaches 50% Recruitment Milestone 25 May 2016 11:23AM $0.305 $0.046 fallen by 84.92%
$15 Appendix 3B & 708A Notice 16 May 2016 5:54PM $0.335 $0.046 fallen by 86.27%
$15 Immuron Announces E-Commerce Agreement with QBID in China 9 May 2016 9:30AM $0.340 $0.046 fallen by 86.47%
$15 US Distribution Reach Expanded through McKesson 28 Apr 2016 9:34AM $0.365 $0.046 fallen by 87.40%
$15 US Travelan Sales Network Widened by Allocation Inc Ptnrship 19 Apr 2016 9:32AM $0.330 $0.046 fallen by 86.06%
$15 Appendix 3B & 708A Notice 18 Apr 2016 6:30PM $0.330 $0.046 fallen by 86.06%
$15 Expansion of US Travelan Sales Following CVS Pharmacy Launch 14 Apr 2016 9:57AM $0.340 $0.046 fallen by 86.47%
$15 Appendix 3B - Issuance of Securities 13 Apr 2016 7:17PM $0.340 $0.046 fallen by 86.47%
$15 Appendix 4D - Half Yearly Report and Accounts 25 Feb 2016 2:40PM $0.390 $0.046 fallen by 88.21%
$15 Appendix 3B - Issue of Securities 24 Feb 2016 5:31PM $0.400 $0.046 fallen by 88.50%
$15 Immuron Initiates Pre-Clinical Colitis Development Program 22 Feb 2016 9:57AM $0.380 $0.046 fallen by 87.89%
$15 Immuron Secures upto $1.7M Equity & Convertible Note Funding 17 Feb 2016 1:20PM $0.410 $0.046 fallen by 88.78%
$15 Immuron Receives $1.47M R&D Tax Concession Refund 4 Feb 2016 12:59PM $0.410 $0.046 fallen by 88.78%
$15 US Analyst Reports on Immuron Products and R&D Pipeline 3 Feb 2016 11:56AM $0.415 $0.046 fallen by 88.92%
$15 Analyst Reports on Immuron IMM-529 C. difficile Program 14 Jan 2016 10:42AM $0.435 $0.046 fallen by 89.43%
$15 IMC Achieves Outstanding Results in C-Diff Recurrence Study 12 Jan 2016 11:26AM $0.400 $0.046 fallen by 88.50%
$15 IMC Reports Highly Successful C-Diff Pre-Clinical Results 22 Dec 2015 10:19AM $0.440 $0.046 fallen by 89.55%

626 - 650 of 782 results

Page 26 of 32

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.